Skip to main content
. Author manuscript; available in PMC: 2018 May 11.
Published in final edited form as: Biotechnol Bioeng. 2017 Jun 29;114(10):2379–2389. doi: 10.1002/bit.26345

Figure 2.

Figure 2

In vitro efficacy of HGFdf on cardiomyocytes. (A) HGFdf significantly enhanced cardiomyocyte viability by 35% as measured by WST-1 metabolic activity assay. (B) HGFdf significantly reduced cardiomyocyte apoptosis by 41% compared to the untreated control as measured by caspase activity (***p<0.001).